Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats

Journal of Hypertension

Volumn 32, Issue 8, 2014, Pages 1637-1649

  Takai, Shinji ^a   Jin, Denan ^a   Chen, Hong ^b   Li, Wen ^c   Yamamoto, Hideyuki ^c   Yamanishi, Kyosuke ^c   Miyazaki, Mizuo ^a   Higashino, Hideaki ^d   Yamanishi, Hiromichi ^d   Okamura, Haruki ^c  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Hirakataryoikuen   (Japan)

Author keywords

chymase; hypertension; inhibitor; macrophage; vascular disease

Indexed keywords

ACETYLCHOLINE; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; GELATINASE B; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TY 51469; UNCLASSIFIED DRUG; RENIN; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; MACROPHAGE; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; DRUG EFFECTS; GENETICS; HEART MUSCLE; HYPERTENSION; METABOLISM; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE; SYSTOLE; VASCULAR ENDOTHELIUM;

ANIMALS; BODY WEIGHT; CHYMASES; ENDOTHELIUM, VASCULAR; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; RATS; RATS, INBRED SHR; RENIN; RNA, MESSENGER; STROKE; SULFONAMIDES; SYSTOLE; THIOPHENES;

EID: 84904036451     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000231     Document Type: Article

References (57)

1. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265: 22348-22357. (Pubitemid 120014308)
2. Takai S, Shiota N, Sakaguchi M, Muraguchi H, Matsumura E, Miyazaki M. Characterization of chymase from human vascular tissues. Clin Chim Acta 1997; 265:13-20. (Pubitemid 27414374)
3. Rouleau A, Garbarg M, Schwartz JC, Ruat M. Molecular cloning of rat mast cell protease 1 and development of specific probes for its gene transcript. Biochem Biophys Res Commun 1994; 199:593-602. (Pubitemid 24181703)
4. Benfey PN, Yin FH, Leder P. Cloning of the mast cell protease, RMCP II. Evidence for cell-specific expression and a multigene family. J Biol Chem 1987; 262:5377-5384.
5. Ide H, Itoh H, Tomita M, Murakumo Y, Kobayashi T, Maruyama H, et al. Cloning of the cDNA encoding a novel rat mast-cell proteinase, rMCP-3, and its expression in comparison with other rat mast-cell proteinases. Biochem J 1995; 311 (Pt 2):675-680.
6. Karlson U, Pejler G, Froman G, Hellman L. Rat mast cell protease 4 is a beta-chymase with unusually stringent substrate recognition profile. J Biol Chem 2002; 277:18579-18585. (Pubitemid 34952410)
7. Karlson U, Pejler G, Tomasini-Johansson B, Hellman L. Extended substrate specificity of rat mast cell protease 5, a rodent alpha-chymase with elastase-like primary specificity. J Biol Chem 2003; 278:39625-39631. (Pubitemid 37248522)
8. Solivan S, Selwood T, Wang ZM, Schechter NM. Evidence for diversity of substrate specificity among members of the chymase family of serine proteases. FEBS Lett 2002; 512:133-138. (Pubitemid 34164466)
9. Guo C, Ju H, Leung D, Massaeli H, Shi M, Rabinovitch M. A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest 2001; 107:703-715. (Pubitemid 32225356)
10. Le Trong H, Neurath H, Woodbury RG. Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci U S A 1987; 84:364-367. (Pubitemid 17006195)
11. Yamamoto D, Shiota N, Takai S, Ishida T, Okunishi H, Miyazaki M. Three-dimensional molecular modeling explains why catalytic function for angiotensin-I is different between human and rat chymases. Biochem Biophys Res Commun 1998; 242:158-163. (Pubitemid 28412395)
12. Okunishi H, Oka Y, Shiota N, Kawamoto T, Song K, Miyazaki M. Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents. Jpn J Pharmacol 1993; 62:207-210. (Pubitemid 23218242)
13. Takai S, Sakaguchi M, Jin D, Yamada M, Kirimura K, Miyazaki M. Different angiotensin II-forming pathways in human and rat vascular tissues. Clin Chim Acta 2001; 305:191-195. (Pubitemid 32201977)
14. Kirimura K, Takai S, Jin D, Muramatsu M, Kishi K, Yoshikawa K, et al. Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 2005; 28:457-464. (Pubitemid 41007461)
15. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997; 273:H1769-H1774.
16. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K. Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998; 32:514-520. (Pubitemid 28429142)
17. Takai S, Jin D, Miyazaki M. New approaches to blockade of the reninangiotensin-aldosterone system: chymase as an important target to prevent organ damage. J Pharmacol Sci 2010; 113:301-309.
18. Takai S, Jin D, Miyazaki M. Multiple mechanisms for the action of chymase inhibitors. J Pharmacol Sci 2012; 118:311-316.
19. Fang KC, Raymond WW, Lazarus SC, Caughey GH. Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. J Clin Invest 1996; 97:1589-1596. (Pubitemid 26105468)
20. Furubayashi K, Takai S, Jin D, Miyazaki M, Katsumata T, Inagaki S, et al. Chymase activates promatrix metalloproteinase-9 in human abdominal aortic aneurysm. Clin Chim Acta 2008; 388:214-216. (Pubitemid 350266567)
21. Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y. Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J Cell Sci 1993; 104:991-999. (Pubitemid 23154306)
22. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, et al. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 2000; 67:585-589.
23. Uehara Y, Urata H, Ideishi M, Arakawa K, Saku K. Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta. Cardiovasc Res 2002; 55:870-876.
24. Bot I, Bot M, van Heiningen SH, van Santbrink PJ, Lankhuizen IM, Hartman P, et al. Mast cell chymase inhibition reduces atherosclerotic plaque progression and improves plaque stability in ApoE-/-mice. Cardiovasc Res 2011; 89:244-252.
25. Takai S, Jin D, Ikeda H, Sakonjo H, Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res 2009; 32:853-860.
26. Takai S, Jin D, Aritomi S, Niinuma K, Miyazaki M. Powerful vascular protection by combining cilnidipine with valsartan in stroke-prone, spontaneously hypertensive rats. Hypertens Res 2013; 36:342-348.
27. Inoue N, Muramatsu M, Jin D, Takai S, Hayashi T, Katayama H, et al. Effects of chymase inhibitor on angiotensin II-induced abdominal aortic aneurysm development in apolipoprotein E-deficient mice. Atherosclerosis 2009; 204:359-364.
28. Takai S, Jin D, Ohzu M, Tanaka K, Miyazaki M. Chymase inhibition provides pancreatic islet protection in hamsters with streptozotocininduced diabetes. J Pharmacol Sci 2009; 110:459-465.
29. Zhong MF, Shen WL, Wang J, Yang J, Yuan WJ, He J, et al. Paradoxical effects of streptozotocin-induced diabetes on endothelial dysfunction in stroke-prone spontaneously hypertensive rats. J Physiol 2011; 589:5153-5165.
30. Nakano A, Inoue N, Sato Y, Nishimichi N, Takikawa K, Fujita Y, et al. LOX-1 mediates vascular lipid retention under hypertensive state. J Hypertens 2010; 28:1273-1280.
31. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55:611-622.
32. Suzuki T, Higgins PJ, Crawford DR. Control selection for RNA quantitation. Biotechniques 2000; 29:332-337. (Pubitemid 30658285)
33. Takai S, Jin D, Sakaguchi M, Katayama S, Muramatsu M, Sakaguchi M, et al. A novel chymase inhibitor, 4-[1-([bis-(4-methyl-phenyl)-methyl]-carbamoyl)3-(2- ethoxy-benzyl)-4-oxo-azetidine-2-yloxy]-ben zoic acid (BCEAB), suppressed cardiac fibrosis in cardiomyopathic hamsters. J Pharmacol Exp Ther 2003; 305:17-23. (Pubitemid 36373831)
34. Oyamada S, Bianchi C, Takai S, Chu LM, Sellke FW. Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/ reperfusion. J Pharmacol Exp Ther 2011; 339:143-151.
35. Ahmed SH, Clark L, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
36. Takahashi K, Takeya M, Sakashita N. Multifunctional roles of macrophages in the development and progression of atherosclerosis inhumans and experimental animals. Med Electron Microsc 2002; 35:179-203. (Pubitemid 36205679)
37. Saha P, Modarai B, Humphries J, Mattock K, Waltham M, Burnand KG, Smith A. The monocyte/macrophage as a therapeutic target in atherosclerosis. Curr Opin Pharmacol 2009; 9:109-118.
38. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res 2009; 29:313-326.
39. Moon SK, Cho GO, Jung SY, Gal SW, Kwon TK, Lee YC, et al. Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. Biochem Biophys Res Commun 2003; 301:1069-1078. (Pubitemid 36279222)
40. Heikkilä HM, Lätti S, Leskinen MJ, Hakala JK, Kovanen PT, Lindstedt KA. Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-(. Arterioscler Thromb Vasc Biol 2008; 28:309-314. (Pubitemid 351187646)
41. Okamoto K, Yamori Y, Nagaoka A. Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 1974; 34 (Suppl I):I-143-I-153.
42. Humphrey JD. Mechanisms of arterial remodelling in hypertension: coupled roles of wall shear an intramural stress. Hypertension 2008; 52:195-200.
43. Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of MMP-1 and MMP-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004; 17:770-774. (Pubitemid 39201091)
44. Fontana V, Silva PS, Belo VA, Antonio RC, Ceron CS, Biagi C, et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: A relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011; 109:130-137.
45. Pires PW, Rogers CT, McClain JL, Garver HS, Fink GD, Dorrance AM. Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2011; 301:H87-H97.
46. Kakimoto K, Takai S, Murano M, Ishida K, Yoda Y, Inoue T, et al. Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. J Pharmacol Exp Ther 2010; 332:684-689.
47. Ishida K, Takai S, Murano M, Nishikawa T, Inoue T, Murano N, et al. Role of chymase-dependent matrix metalloproteinase-9 activation in mice with dextran sodium sulfate-induced colitis. J Pharmacol Exp Ther 2008; 324:422-426. (Pubitemid 351185847)
48. Shiota N, Rysä J, Kovanen PT, Ruskoaho H, Kokkonen JO, Lindstedt KA. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens 2003; 21:1935-1944. (Pubitemid 37290113)
49. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 2002; 105:753-758. (Pubitemid 34157381)
50. Lindsey ML, Escobar GP, Dobrucki LW, Goshorn DK, Bouges S, Mingoia JT, et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 290:H232-H239.
51. Longley BJ, Tyrrell L, Ma Y, Williams DA, Halaban R, Langley K, et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci U S A 1997; 94:9017-9021. (Pubitemid 27357774)
52. Tsunemi K, Takai S, Nishimoto M, Jin D, Sakaguchi M, Muramatsu M, et al. A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6- dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl] acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 2004; 309:879-883. (Pubitemid 38669674)
53. Maruichi M, Takai S, Sugiyama T, Ueki M, Oku H, Sakaguchi M, et al. Role of chymase on growth of cultured canine Tenon's capsule fibroblasts and scarring in a canine conjunctival flap model. Exp Eye Res 2004; 79:111-118. (Pubitemid 38737388)
54. Roszkowska-Chojecka M, Walkowska A, Gawrysl O, Olszyn'ski K, Kompanowska-Jezierska E. Effects of chymostatin, a chymase inhibitor, on blood pressure and kidney haemodynamics in different models of hypertension in the rats. Nephrol Dial Transplant 2013; 28 (Supplement 1):i325-i326; (Abstract).
55. Takai S, Jin D, Nishimoto M, Yuda A, Sakaguchi M, Kamoshita K, et al. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 2001; 69:1725-1732. (Pubitemid 32781760)
56. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281-1357.
57. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)